USA flag logo/image

An Official Website of the United States Government

USING NOVEL LAYERED MEMBRANES IN CLINICAL PROTEOMICS

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
70543
Program Year/Program:
2004 / SBIR
Agency Tracking Number:
CA096238
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
20/20 GENESYSTEMS, INC.
9430 Key West Ave. Suite 100 ROCKVILLE, MD 20850-6347
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2004
Title: USING NOVEL LAYERED MEMBRANES IN CLINICAL PROTEOMICS
Agency: HHS
Contract: 1R43CA096238-01A2
Award Amount: $99,378.00
 

Abstract:

DESCRIPTION (provided by applicant): Personalized medicine" is a new clinical paradigm where a specific cancer therapeutic ("smart drug") is prescribed based upon the individual biology of the patient. A goal of personalized medicine is to select individual therapies based upon the correlation of proteomic profiles from diseased tissues with patient response to drug therapy. Therefore, there is a critical need for a practical tool that can generate protein expression profiles from small amounts of tissue samples collected from patients. We hypothesize that cancer patients will be treated more successfully if a correlation between proteomic profiles and drug efficacy is established and that a diagnostic test using our innovative and novel technology, Layered Protein Scanning (LPS), will be able to establish that correlation. The long-term goal of this proposal is to, by the end of Phase II, develop a clinical diagnostic tool that would be used to select and monitor patients most likely to respond to "smart drugs". To establish proof of principle, in Phase I, we will test the ability of LPS to profile Epidermal Growth Factor Receptor (EGFr) activity in head and neck squamous cell carcinoma cell lines and tissues. Specifically, we will use Layered Protein Scanning to quantitate the differences in activity of EGFr, Erkl/2, and Stat3 in: 1) Cell line samples (by comparing LPS-tissue blot with standard western blot) 2) Tissue sections of HNSCC (by comparing LPS-tissue blot to immunohistochemistry).

Principal Investigator:

Vladimir Knezevic

Business Contact:

Jonathan Cohen
3014242032
JCOHEN@2O2OGENE.COM
Small Business Information at Submission:

TWENTY-TWENTY GENE SYSTEMS
TWENTY-TWENTY GENE SYSTEMS 113 N WASHINGTON ST, #424 ROCKVILLE, MD 20850

EIN/Tax ID: 522272107
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No